Akebia Therapeutics, Inc. (AKBA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.97-0.87%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Manage Auryxia revenue decline due to competition: rev -21.0% vs contained decline target.
Akebia is growing Vafseo revenue by expanding dialysis access. The company manages Auryxia's revenue decline due to competition. Recent M&A activity strengthens its rare kidney disease pipeline. Revenue is expected near $59 million in 2025. Profitability is improving from prior losses.
Revenue is expected to decline about 22% next year. The company remains unprofitable with negative EPS forecasts. Competition pressures Auryxia sales and cash flow. Market doubts durable growth and turnaround progress.
The market expects about 22% revenue decline next year and continued losses. Our view sees potential for stabilization and growth from Vafseo uptake and pipeline expansion, which is not fully reflected in current estimates.
Breaks if: Auryxia revenue declines faster than expected or accelerates loss
Breaks if: pipeline milestones delayed or acquisitions fail to integrate
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround opportunity in the healthcare sector. AKBA is currently navigating challenges with its product revenues while focusing on expanding its dialysis access revenue and advancing clinical trials.
The market appears to reflect a low expectations gap, suggesting that AKBA is priced relatively cheaply compared to its peers. However, the overall valuation is justified given the company's loss-making status and recent performance.
Management is making progress in expanding Vafseo revenue, which saw significant growth recently. However, Auryxia's revenue decline due to competition remains a concern, and the company is facing a high probability of missing earnings expectations in the near term.
The thesis hinges on management's ability to maintain revenue growth from Vafseo and successfully navigate the competitive landscape for Auryxia. Additionally, broader sector performance and potential earnings guidance changes will be critical factors to watch.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: total revenue falls below $58 million in FY25
Grow Vafseo net product revenues by increasing patient numbers, prescribers, and market penetration in dialysis organizations.
Stated as a priority in 2 of last 2 quarters. Vafseo net product revenues increased from $15.8 million in 2026-Q1 to $21.3 million in 2026-Q2, a 34% sequential growth. Patient count on therapy rose 41% over the same period. Management is delivering on expanding Vafseo revenue through dialysis access.
“Vafseo net product revenues grew to $21.3 million in Q2, representing a 34% increase over Q1 of this year.”
“Vafseo net product revenues grew to $15.8 million in Q1; number of patients on Vafseo increased 60% in Q1 compared to Q4 2025.”
Breaks if: Vafseo revenue growth fails to materialize or declines over next 4 quarters
Grow Vafseo net product revenues by increasing patient numbers, prescribers, and market penetration in dialysis organizations.
Stated as a priority in 2 of last 2 quarters. Vafseo net product revenues increased from $15.8 million in 2026-Q1 to $21.3 million in 2026-Q2, a 34% sequential growth. Patient count on therapy rose 41% over the same period. Management is delivering on expanding Vafseo revenue through dialysis access.
“Vafseo net product revenues grew to $21.3 million in Q2, representing a 34% increase over Q1 of this year.”
“Vafseo net product revenues grew to $15.8 million in Q1; number of patients on Vafseo increased 60% in Q1 compared to Q4 2025.”
Over the next 1 to 3 years, AKBA's performance will depend on its execution in revenue generation and clinical advancements. Not investment advice.